Purdue Pharmaceuticals, L.P.
One Stamford Forum
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
214 articles with Purdue Pharmaceuticals, L.P.
The notorious legacy of OxyContin continues to be a major black mark against Purdue Pharmaceuticals. And that mark is only getting worse as a court case against the opioid manufacturer has revealed company officials used deceptive marketing practices to boost sales of the drug.
Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
Eisai Co., Ltd. and Purdue Pharma L.P. today announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder.
Eisai Co., Ltd. and Purdue Pharma, L.P. announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder.
1/10/2019Opioid drugmakers being sued in the state of Connecticut are breathing a big sigh of relief today after a judge dismissed lawsuits filed by 37 different municipal governments.
Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain
Partners to research novel targets for reductions in pain
Now open at The University of Texas MD Anderson Cancer Center, the open-label, non-randomized trial will investigate the safety profile, maximum tolerated dose, and efficacy of tinostamustine.
Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain
Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near the spine
10/19/2018As more and more lawsuits are filed by state and local governments over the opioid epidemic, drugmakers are fighting back in court by demanding the allegations include specifics on how the companies are to blame.
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy objectives
10/17/2018Eisai Co. and Purdue Pharma announced topline results from their SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.
Opioid manufacturers have been the target of thousands of lawsuits from state and local governments seeking to reclaim funds that have been spent on addressing treatment for opioid abuse and overdoses.
In a 99 to 1 vote, the Senate passed the bill that looks to cut down on the flow of illegal narcotics entering the United States through the mail, as well as taking aim at the abuse of prescription opioid medication – a problem that has grown to an epidemic in the United States.
Purdue Pharma, best known for being the manufacturer of opioid drug OxyContin, is offering free doses of a treatment for opioid abuse as part of negotiations in more than 1,000 lawsuits.
Purdue Pharma L.P. and Geisinger Present Interim Analysis from Wearable Health Technology Clinical Trial at PAINWeek® 2018 Annual Conference
Results Show Successful Uptake of Technology and Increased Patient-Provider Communication
Studies Underscore Company’s Ongoing Commitment to Working Collaboratively on Meaningful Solutions to Address the Opioid Crisis.
Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Work to Develop Inexpensive, Over-the-Counter, Life-Saving Naloxone in the United States
Naloxone is an opioid antagonist used to reverse the effects of a life-threatening opioid overdose.
Purdue Pharma (Canada) announces today that BETADINE® Sore Throat Spray and BETADINE® Sore Throat Gargle launched on August 3, 2018.
Posters Include Interim Data from Wearable Health Technology Study and Research Initiatives to Evaluate Prescription Drug Monitoring, Take Back Programs, and Factors Influencing Opioid Use Disorder Diagnosis
President Donald Trump has called on U.S. Attorney General Jeff Sessions to file lawsuits against certain drug manufacturers whose drugs have contributed to the opioid crisis.